As such, mGlu2/3 receptors have drawn increasing attention as robust regulators of synaptic transmission and plasticity and potential targets for developing novel pharmacotherapies for various brain disorders (reviewed in Muguruza et al., 2016; Chaki, 2017; Maksymetz et al., 2017; Mazzitelli et al., 2018; Sebastianutto and Cenci, 2018). The gene discussed is GRM2; the disease is brain disorder.